GTS Securities LLC Makes New $3.60 Million Investment in Novo Nordisk A/S $NVO

GTS Securities LLC purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 75,048 shares of the company’s stock, valued at approximately $3,598,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $25,000. Transamerica Financial Advisors LLC raised its stake in Novo Nordisk A/S by 201.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after purchasing an additional 403 shares during the period. Johnson Financial Group Inc. boosted its holdings in Novo Nordisk A/S by 128.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock valued at $38,000 after purchasing an additional 384 shares during the last quarter. Scarborough Advisors LLC acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $26,000. Finally, Kingdom Financial Group LLC. purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent analyst reports. BMO Capital Markets restated a “market perform” rating and set a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday, August 6th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Berenberg Bank set a $47.00 target price on Novo Nordisk A/S in a research report on Wednesday, August 12th. Weiss Ratings raised Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: China’s drug regulator accepted Novo Nordisk’s application for an oral version of Wegovy, an important regulatory milestone that could broaden access to its obesity treatment and support future growth in a major market. China drug regulator accepts Novo Nordisk’s application for oral Wegovy
• Positive Sentiment: Some investors view Novo Nordisk as potentially undervalued following its selloff. A report also suggests that shifting legal risks surrounding compounded or competing GLP-1 products could improve the outlook for branded treatments such as Ozempic and Wegovy. Novo Nordisk stock may be cheap as GLP-1 legal risks shift
• Neutral Sentiment: Novo Nordisk’s U.S. shares recently traded near $46, below the 50-day average but above the 200-day average. Its relatively low forward valuation may limit downside for value-oriented investors, but the stock’s price-to-earnings-growth ratio indicates that a recovery is not yet fully reflected in earnings expectations.
• Negative Sentiment: Deutsche Bank downgraded Novo Nordisk from Hold to Sell and cut its price target from 290 to 265 Danish kroner. The bank cited doubts about a return to growth, intensifying competition from Eli Lilly, a looming patent-related revenue cliff and weakness in the company’s development pipeline. Deutsche Bank cuts Novo Nordisk to Sell after earnings
• Negative Sentiment: Investor concerns were reinforced by mixed second-quarter results and the late-stage failure of cardiovascular drug candidate Ziltivekimab, which Deutsche Bank reportedly considers effectively removed from the company’s near-term growth prospects. Novo’s 2027 growth rebound faces fresh doubts

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $45.59 on Friday. The stock has a market capitalization of $203.56 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 4.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a 50-day moving average of $48.03 and a 200 day moving average of $43.90. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The business had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.45 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. Novo Nordisk A/S’s payout ratio is 20.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.